Biotechnology News and Research

RSS

CONNECT announces the winners of MIP Awards

CONNECT, one of the nation's most successful regional economic development programs for high technology and life science innovators, today announced the winners of the 22nd Annual Most Innovative New Product (MIP) Awards.

11 Dec 2009

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Seattle Genetics, Inc. today reported that it has been notified by Genentech, a wholly owned member of the Roche Group, that Genentech has elected to terminate the companies’ collaboration agreement for dacetuzumab (SGN-40). Dacetuzumab is a monoclonal antibody targeting CD40 that has been investigated in clinical trials for non-Hodgkin lymphoma and multiple myeloma.

11 Dec 2009

Uppsala University Hospital orders CELDA from Likvor for diagnosing NPH

LinkMed’s portfolio company Likvor has received an order for Likvor CELDA™ from Uppsala University Hospital (Akademiska Universitetssjukhuset).

11 Dec 2009

PharmMD raises $8.8 million in capital from The Riverside Company and FCA Ventures IV

PharmMD recently raised $8.8 million in capital from The Riverside Company and FCA Ventures IV, a fund of Clayton Associates.

11 Dec 2009

Study describing solid-state characterization of three forms of finasteride published

Aptuit, Inc. today announced the publication of new research in the December issue of the European Journal of Pharmaceutical Sciences, the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS), which describes the solid-state characterization of three forms of finasteride.

11 Dec 2009

Update on proposed transaction that will lead to the merger of Cytopia into YM BioSciences provided

YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today provided an update on the proposed transaction which would result in the merger of Cytopia Ltd. into YM, details of which were announced on October 5, 2009.

11 Dec 2009

ThromboGenics initiates Phase II trial of microplasmin for wet AMD

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

11 Dec 2009

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks.

11 Dec 2009

Researchers discover new explanation for differences in severity of mental illness in males

Researchers have discovered a new explanation for differences in the severity of mental illness in males. The more excess copies of a certain gene, the more serious the handicap. The genetic defect is situated on the X-chromosome; and it is suspected that it is the amount of copies of the GDI1 gene that is responsible.

11 Dec 2009

HST Global and HMD team up to develop curriculum for FIT protocol

HST Global, Inc. (OTCBB: HSTC) today announced a Partnership with Dr. James W. Forsythe to facilitate the development of a curriculum for the licensing and/or certification to administer Dr. Forsythe’s immune therapy in clinics to be built or acquired by HST Global, Inc.

11 Dec 2009

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product “ATI-1123,” a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.

10 Dec 2009

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

Enzo Biochem, Inc. announced today that its Enzo Clinical Lab division has entered into an exclusive marketing partnership covering the States of New York and New Jersey with privately-owned Ikonisys, Inc., of New Haven, CT, relating to Ikonisys’ proprietary oncoFISH® cervical test, a laboratory developed test for cervical cancer prevention.

10 Dec 2009

InNexus Biotechnology, XERIS Pharmaceuticals collaborate in development of novel antibody delivery system

InNexus Biotechnology Inc. and XERIS Pharmaceuticals, Inc. announced today a research collaboration in which the companies will pursue development of a potential subcutaneous delivery of InNexus’ Dynamic Cross Linking (DXL™) antibodies using XERIS’ proprietary formulation-injection technologies.

10 Dec 2009

Vicor's PD2i nonlinear algorithm selected for CRY cardiac screening initiative

David H. Fater, CEO of Vicor Technologies, Inc., today announced that its PD2i® nonlinear algorithm has been selected by Dr. Sanjay Sharma to be used in a month-long cardiac screening initiative to be held in South East London in April 2010.

10 Dec 2009

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

Oncothyreon Inc. today announced that Merck KGaA of Darmstadt, Germany, has initiated a Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The trial, named INSPIRE (Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response), is anticipated to enroll approximately 420 patients in China, Hong Kong, South Korea, Singapore and Taiwan.

10 Dec 2009

YM BioSciences announces results of collaborative antibody development program

YM BioSciences Inc., today announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface receptors associated with cancer, uniquely optimized to produce efficacy with reduced toxicities.

10 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Convergence between EDC and RTSM solutions simplifies workflow management

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today introduced unique product convergence between its DataLabs® EDC solution and ClinPhone® Randomization and Trial Supply Management (RTSM) technologies.

From Parexel 10 Dec 2009

Public health information website to provide information about advanced disinfectants launched

TouchSurfaces.Org launches a public health information website alerting visitors on how the hard surfaces in the home, the work place, and in public venues can act as host to a multitude of infectious viruses and bacteria including H1N1, MRSA, HIV, and others.

10 Dec 2009

Biotechnology News and Research

CONNECT announces the winners of MIP Awards

Zevalin clinical data presented at 2009 ASH meeting

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Uppsala University Hospital orders CELDA from Likvor for diagnosing NPH

PharmMD raises $8.8 million in capital from The Riverside Company and FCA Ventures IV

Study describing solid-state characterization of three forms of finasteride published

Update on proposed transaction that will lead to the merger of Cytopia into YM BioSciences provided

ThromboGenics initiates Phase II trial of microplasmin for wet AMD

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Researchers discover new explanation for differences in severity of mental illness in males

HST Global and HMD team up to develop curriculum for FIT protocol

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

InNexus Biotechnology, XERIS Pharmaceuticals collaborate in development of novel antibody delivery system

Vicor's PD2i nonlinear algorithm selected for CRY cardiac screening initiative

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

YM BioSciences announces results of collaborative antibody development program

Eli Lilly provides financial guidance for 2010

Convergence between EDC and RTSM solutions simplifies workflow management

Public health information website to provide information about advanced disinfectants launched

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News